Company Overview
MediWound Ltd. operates within the healthcare sector, specifically focusing on the biotechnology industry where it develops, manufactures, and commercializes novel bio-therapeutic and non-surgical solutions designed for tissue repair and regeneration. The company's product portfolio includes the marketing of NexoBrid, a biopharmaceutical product intended for use in the United States, Germany, Italy, Spain, and various international markets. As a biopharmaceutical entity, MediWound engages in the complex process of creating specialized medical treatments that address specific clinical needs in wound care and tissue regeneration. The company maintains a workforce of 121 employees who support these R&D and commercialization efforts across its geographic footprint. In terms of scale, the organization holds a market capitalization of $218.12M and generated annual revenue of $16.96M over the trailing twelve months. These figures indicate that MediWound is a small-cap entity with a market valuation significantly lower than large-cap pharmaceutical peers, suggesting a position typical for a company still in the growth or development phase within the specialized biotechnology landscape.
Financial Health
The company reported revenue of $16.96M for the trailing twelve months, yet this generated a net income of -$23,879,000 and an EBITDA of -$24,280,000. The substantial gap between the positive revenue of $16.96M and the deeply negative net income of -$23.879M reveals a highly leveraged cost structure where operating expenses and research costs far exceed the revenue generated by current product sales. The free cash flow stands at -$15,578,875, indicating that the company is burning through cash reserves to fund its operations and development pipeline rather than generating surplus liquidity. Despite these outflows, the company holds a cash balance of $53.14M, which provides a buffer against its total debt of $8.78M. The debt-to-equity ratio is recorded at 20.11, suggesting a balance sheet that is leveraged relative to its equity base, though the high cash position mitigates immediate solvency risks. Liquidity is supported by a current ratio of 2.33, which indicates that the company possesses more than twice the current assets needed to cover its short-term liabilities. Return on Equity is -63.9% and Return on Assets is -19.8%, metrics that reveal the company is currently utilizing its capital and assets to generate losses rather than positive returns for shareholders or asset holders.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is -7.82, a negative figure that implies the market is pricing in future earnings expectations that have not yet materialized in the current period. The price-to-book ratio stands at 5.00, indicating that the market values the company at five times its book value, a significant premium often seen in biotechnology firms with intangible assets like intellectual property and clinical data. Alternative valuation metrics such as the price-to-sales ratio of 12.86 and an EV/EBITDA of -7.16 suggest that investors are valuing the company based on revenue potential and future growth prospects rather than current profitability. The stock trades with a 52-week high of $22.50 and a 52-week low of $14.14, meaning the current price sits within a range that reflects recent volatility but remains below the annual peak. The beta value is 0.12, which indicates that the stock price exhibits very low volatility relative to the broader market, moving less than one-eighth as much as the overall index during periods of market fluctuation.
Growth & Income
Revenue growth year-over-year is -68.0%, while earnings growth is N/A, indicating that the company is currently contracting in terms of top-line revenue generation. Because earnings are not growing, there is no divergence between revenue and earnings trajectories to analyze, as the negative revenue growth directly impacts the bottom line. MediWound does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all available capital back into its operations, research, and development activities rather than distributing cash to shareholders. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, reflecting the typical financial stage of a biotechnology company focused on product development and market expansion rather than mature cash flow generation.